EGFR and non-small cell lung carcinoma: The purpose of this study was to explore predictive biomarkers for ICI response using plasma samples collected after EGFR-TKI therapy.<h4>Methods</h4>This retrospective analysis included 28 patients with EGFR-mutant NSCLC treated with an ICI after developing resistance to EGFR-TKI.